The domestic market is reacting, after the 4-day downward streak that preceded it, which was a result of the lack of positive catalysts. In contrast to previous days, Athens is tuning in today (12/9) to the rally in international stock markets. The resurgence of buying interest is driven by Wall Street’s tech rally, as well as the boost provided to euro markets by the ECB’s monetary easing.
Specifically, in Thursday’s session the General Index is up +0.67% to trade at 1,423 points, moving between 1,418.81 (low of the day) and 1,425.17 (high of the day). According to analysts, the key issue in case of a setback is not to miss other critical technical boundaries, such as 1,400 points.
Investors welcome ElvalHalcor with a strong rise in the wake of the results announced yesterday. However, the same is not true for Aegean, as the airline’s shares are under pressure at the start.
The impending private placement for 8% to 10% of the total 18.39% held by the HFSF in National Bank is leading investors in recent days to strategically raise funds so that they are ready when the placement is carried out, most likely in early October.
Moody’s will release its assessment of the Greek economy on Friday evening (13/9). The American house is the only one to place Greece one notch below investment grade, at Ba1 with a stable outlook.
Lamda Development and Hellaktor among the high-capitalization listed companies, as well as the “smaller” companies Geniki Emporio & Industrie and Klukinas – Lappas announce their first-half financial results today. Before the start of trading, Alpha Trust – Andromeda announced its half-year performance, distributing an additional dividend of EUR 0.17 per share.
Today, the 5.55 million new shares of Attica Bank, resulting from its merger with Pancretia Bank, will be put up for trading. At the same time, the trading of approximately 12.33 million Eurobank shares, which resulted from the recent share capital increase, due to the exercise of stock options by 221 executives of the bank, with an offer price of EUR 0.23, begins. Without the right to the dividend of EUR 0.05, Evrofarma shares are currently trading, while Unibios shares are trading without the right to the capital return of EUR 0.02.
